Abstracts

Molecular Epidemiology of Human Mpox in Chicago

Background: Mpox (formerly known as monkeypox) is a syndrome of fever, rash, and lymphadenopathy caused by the mpox virus (MPXV), a zoonotic double-stranded DNA orthopoxvirus. The virus was first isolated in monkeys from Singapore in 1959 and is now known to have several animal reservoirs. Since its emergence in humans in the 1970’s, MPXV has…

Mpox Virus Model of Sexual Transmission in Cynomolgus Macaque

Background: The Monkeypox virus (MPXV) responsible for 2022 outbreak belongs to clade IIb which derives from the less virulent clade and whose exact mode transmission needs to be established. Monkeypox (Mpox) mainly affects male population and evidence suggest that Mpox could be a sexually transmitted disease. Today, the animal models of Mpox and more particularly…

Tecovirimat Plasma Concentrations, Mpox Resistance Mutations Selection, and Clinical Outcomes

Background: During the recent Mpox outbreak, Tecovirimat was used to treat patients with severe disease. There are few studies characterizing Tecovirimat resistance mutations and none describing concomitant drug plasma concentrations. Methods: Two HIV-1 infected patients hospitalized for severe and persistent Mpox clinical manifestations were studied. Sequential sampling of several anatomic compartments were screened for Mpox…

Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced HIV Infection

Background: Appropriate therapeutic management of mpox in people with advanced HIV remains challenging given an absence of clinical trial evidence. This case series aims to provide our experience during the 2022 outbreak for patients with severe mpox treated aggressively with a combination of extended tecovirimat and cidofovir with antiretrovirals (ART). Methods: This is a retrospective…

Orthopoxvirus-Specific IgG Upon Mpox Vaccination Among People With and Those Without HIV

Background: In Taiwan, nationwide routine and compulsory smallpox vaccination with Lister strain had been stopped in 1979. As Mpox continued to spread worldwide, a two-dose Mpox vaccination, with an interval of at least 28 days, is currently recommended as pre- and post-exposure prophylaxis in the high-risk populations. However, orthopoxvirus-specific (OPXV) IgG remains less investigated in…

Long Half-Life Broadly Neutralizing Killer Bispecifics Against HIV-1: Harnessing the Immune System

Background: HIV-1 remains significant global health challenge, requiring continuous efforts to develop innovative therapeutic approaches. Clinical use of mAb needs multiple infusions and for BiTEs is limited by short half-life in blood, demanding continuous infusion resulting in high costs inconvenience and time-consumption. We describe the development of DNA-launched, bispecific T cell engagers that redirect T…

Targeting HIV-Infected Cells for Immunotherapy Through HLA-E

Background: Cytolytic T lymphocytes (CTLs) help control viremia in people with HIV. HIV evades this response through escape mutations in CTL epitopes and downregulation of HLA molecules. The dimorphic non-canonical HLA-E molecules, however, are upregulated during infection, making them promising targets for CTL-engaging reagents such as single-chain diabodies (scDbs) provided that they present HIV epitopes.…

Safety of Therapeutic HIV-1 Vaccine for Adolescents with Early Treated Perinatal HIV Infection

Background: HVRRICANE is a phase I, proof of concept, open-label, randomized clinical trial to evaluate safety, immunogenicity and efficacy in HIV reservoir reduction of a prime-boost strategy with a multigene, multi-subtype A, B, C HIV-DNA vaccine (HIVIS DNA) and modified vaccinia Ankara Chiang Mai Double Recombinant (MVA-CMDR) vaccine ± co-administration of Toll-like Receptor 4 agonist…